NX1 Nexalis Therapeutics Limited
—Mkt Cap: —P/E: —1d ago
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value1.52M USD
Revenue (TTM)736.07K USD
Gross Profit736.07K USD
Net Income (TTM)-1.12M USD
Revenue/Share0.0050 AUD
Last Price—
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000456733
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue2.07
P/S2.14
P/B-1.29
EPS (TTM)-0.01
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-186.87%
EBITDA Margin0.00%
Profit Margin-193.63%
ROE137.77%
ROA-133.99%
Growth
Revenue Growth14.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-532.36K USD
CapEx (TTM)—
FCF Margin-11.03%
FCF Yield—
Net Debt-49.24K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.63
Current Ratio0.46
Quick Ratio0.44
Book Value/Sh-0.0070 AUD
Cash/Share0.0030 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.253.04M
Float79.90M
Insiders51.64%
Institutions0.00%
Technical
SMA 500.0114 AUD
SMA 2000.0178 AUD
Beta-0.02
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)2.06K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—